Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Abstract Background Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techn...

Full description

Bibliographic Details
Main Authors: Ioannis Iakovou, Evanthia Giannoula, Areti Gkantaifi, Sofia Levva, Savvas Frangos
Format: Article
Language:English
Published: SpringerOpen 2018-10-01
Series:European Journal of Hybrid Imaging
Subjects:
Breast cancer
Nuclear medicine
Molecular imaging
Positron emission tomography (PET)
Immunohistochemistry
Radiopharmaceuticals
Online Access:http://link.springer.com/article/10.1186/s41824-018-0039-x

Internet

http://link.springer.com/article/10.1186/s41824-018-0039-x

Similar Items